MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT)

Similar documents
3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD

Imaging to select patients for Transcatheter TV

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Right Heart Hemodynamics: Echo-Cath Discrepancies

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

Management of TR in Patients Undergoing Mitral Interventions

When Does 3D Echo Make A Difference?

Management of Tricuspid Regurgitation

Tricuspid and Pulmonary Valve Disease

What echo measurements are key prior to MitraClip?

How to assess ischaemic MR?

Elections to EACVI Board

Functional Mitral Regurgitation

Disclosures Rebecca T. Hahn, MD, FASE

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Index. B B-type natriuretic peptide (BNP), 76

Prof. JL Zamorano Hospital Universitario Ramón y Cajal

Assessment of Tricuspid and Pulmonic Valve Disease: Importance of 3D

Tricuspid and Pulmonary Valve Disease

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Primary Mitral Regurgitation

ΓΙΩΡΓΟΣ ΜΑΚΑΒΟΣ, MD, PhD ΚΑΡΔΙΟΛΟΓΟΣ, ΕΠΙΜΕΛΗΤΗΣ Β Γ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Γ.Ν.Ν.Θ.Α. ΣΩΤΗΡΙΑ

JOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

Department of Cardiac, Thoracic and Vascular Sciences University of Padua Cardiac Tamponade. Echocardiography in Diagnosis and Management

Echocardiographic Evaluation of Primary Mitral Regurgitation

Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Part II: Fundamentals of 3D Echocardiography: Acquisition and Application

DECLARATION OF CONFLICT OF INTEREST

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Atrioventricular valve repair: The limits of operability

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Ischemic Mitral Regurgitation

Assessing the Impact on the Right Ventricle

Organic mitral regurgitation

Next Generation Therapies: Aortic, Mitral and Beyond

8/31/2016. Mitraclip in Matthew Johnson, MD

Guidelines in perspective?

Echo in Asymptomatic Mitral and Aortic Regurgitation

Professors Carpentier and McGoon Mechanism, resulting from the disease Severity of regurgitation, resulting from the mechanism Echo

What are the best diagnostic tools to quantify aortic regurgitation?

The Tricuspid Valve: The Not So Forgotten Valve. Manuel J Antunes Cardiothoracic Surgery Coimbra, Portugal

Surgical repair techniques for IMR: future percutaneous options?

Concomitant Tricuspid Valve Repair :

Mitral Regurgitation

Cover Page. The handle holds various files of this Leiden University dissertation.

Outline. EuroScore II. Society of Thoracic Surgeons Score. EuroScore II

Prognostic Impact of FMR

Use of MitraClip Beyond Everest Criteria

New 3D Quantification of Mitral Regurgitation Severity. Judy Hung, MD Cardiac Ultrasound Laboratory Massachusetts General Hospital Boston, MA

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

What is the Role of Surgical Repair in 2012

Regurgitant Lesions. Bicol Hospital, Legazpi City, Philippines July Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

Marti McCulloch, BS, MBA, RDCS, FASE Houston, Texas

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Quality Outcomes Mitral Valve Repair

Techniques for ischemic mitral valve disease: An Update. Stanford CV Surgery

Repair or Replacement

Percutaneous Mitral Valve Intervention: QuantumCor Device

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Quantifying Aortic Regurgitation

Despite advances in our understanding of the pathophysiology

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

True morphology of mitral regurgitant flow assessed by three- dimensional transesophageal echocardiography

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Chronic Ischemic Mitral Regurgitation

Surgery For Ebstein Anomaly

Risk Analysis of the Long-Term Outcomes of the Surgical Closure of Secundum Atrial Septal Defects

ΔΙΑΔΕΡΜΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΟΜΙΚΩΝ ΠΑΘΗΣΕΩΝ: Ο ΡΟΛΟΣ ΤΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΣΤΟ ΑΙΜΟΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ ΣΤΗΝ ΤΟΠΟΘΕΤΗΣΗ MITRACLIP

I have financial relationships to disclose Honoraria from: Edwards

Objectives. Considerations in management of multivalvular disease. Case Discussions. A Systematic Approach to Multivalve Disease.

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Trans-catheter TV repair Leaflet or Annuloplasty Techniques

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.

Echocardiography. Guidelines for Valve and Chamber Quantification. In partnership with

MitraClip in the ICCU: Which Patient will Benefit?

10 ο ΣΥΝΕΔΡΙΟ ΕΠΕΜΒΑΤΙΚΗΣ ΚΑΡΔΙΟΛΟΓΙΑΣ ΚΑΙ ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ Σεπτεμβρίου 2017 Electra Palace Θεσσαλονικη

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Aortic Regurgitation and Aortic Aneurysm - Epidemiology and Guidelines -

Haiping Wang 1,2, Xiancheng Liu 2, Xin Wang 2, Zhenqian Lv 2, Xiaojun Liu 2, Ping Xu 1. Introduction

Transcatheter Mitral Valve Replacement How Close Are We?

Aortic stenosis with concomitant mitral regurgitation

Valve Disease Board Review Questions

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Percutaneous mitral annuloplasty. Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy

Echocardiographic evaluation of mitral stenosis

MR echo case. N.Koutsogiannis Department of Cardiology University Hospital Of Patras

Case Studies in Complex Endocarditis

Transcription:

UNIVERSITY OF PADUA, SCHOOL OF MEDICINE Department of Cardiac,Thoracic and Vascular Sciences Padua, Italy MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT) Luigi P. Badano**, MD, PhD, FESC, FACC **Dr. Badano has received honoraries and research grants from GE Healthcare, EsaOte, Samsung Elect, Sorin cardio S.p.A., Siemens, Actelion, Edwards Lifesciences *No off-label use of device

Pathophysiology of Functional Tricuspid Regurgitation Badano LP, Muraru D, Enriquez-Sarano M. Eur Heart J 2013

Tricuspid Regurgitation and Survival Nath, J. et al. J Am Coll Cardiol 2004 Shiran A et al, J Am Coll Cardiol 2009

Changing Paradigms About Tricuspid Regurgitation "TV is not so important as left valves and severe TR is relatively benign... TR is an independent determinant of patients survival and is associated with significant morbidity Functional (secondary) TR spontaneously disappears after correction of the mitral valve disease Functional TR does not resolve after leftsided valve surgery and actually worsens, with tricuspid annular dilation as the most important cause and target for intervention. TR frequency is expected to decrease, due TR frequency is expected to increase, as to the progressively lower prevalence of patients live longer and percutaneous rheumatic MV disease interventions for left-sided valves (TAVI, Mitral clip etc) will be increasingly offered as alternative to traditional surgery. Residual TR immediately after tricuspid valve repair will improve with time TV replacement is better than a poor TV annuloplasty with residual or recurrent TR Braunwald NS et al. Circulation 1967 Dreyfus G. et al. Ann Thorac Surg 2005

Comprehensive Assessment of the Tricuspid Valve Apparatus

Functional Tricuspid Regurgitation: Anatomy Badano LP, Muraru D, Enriquez-Sarano M. Eur Heart J 2013

Functional Tricuspid Regurgitation: Grading Severity

Tricuspid Regurgitation: Grading Severity Lancellotti P et al. Eur Heart J Cardiovasc Imaging 2013

Severity of Functional Regurgitation VD AD VD AD Muraru D, Badano L et al. Curr Cardiol Rep 2011

Quantitation of Functional Regurgitation Vena contracta area Vena contracta area and TR severity: <0.5 cm2 Mild 0.5-0.75 cm2 Moderate >0.75 cm2 Severe Velayudhan DE et al. Echocardiography 2006

Quantitation of Functional Regurgitation Chen TE et al. J Am Soc Echocardiogr 2013

Quantitation of Functional Regurgitation Chen TE et al. J Am Soc Echocardiogr 2013

Quantitation of Functional Regurgitation: 3D PISA Courtesy of Miglioranza MH, data on file

Quantitation of Functional Regurgitation: 3D PISA Courtesy of Miglioranza MH, data on file

Tricuspid Annulus Size 1= 2.6 cm 1= 2.6 cm 2= 3,8 cm 3= 2.9 cm Badano LP et al. Eur J Echocardiogr 2009

Tricuspid Annulus Geometry Maffessanti F et al. Eur Heart J Cardiovasc Imaging 2013

Tricuspid Annulus Size and Shape Changes in Functional Tricuspid Regurgitation Ton-NU T et al. Circulation 2006

How to Measure Tricuspid Annulus by 2D? Miglioranza MH, et al. J Am Soc Echocardiogr 2014 (in press)

How to Measure Tricuspid Annulus by 2D? 219 healthy volunteers (aged 43±15 years, range 18-76 years, 95 men) Linear measurements of TV annulus in 3 different views by 2D echo Miglioranza MH, et al. J Am Soc Echocardiogr 2014 (in press)

Dedicated Software for TV Quantitative Analysis by Transthoracic 3DE Volume rendering (surgical view) Automatically traced leaflets Red color denotes flail leaflet Different colors for each leaflet Annulus size and shape 3D TV computed by the software Veronesi F et al. EuroECHO 2013 (P891)

Tricuspid Annulus in Functional Regurgitation 24 pts with severe (30%) and non severe (70%) functional tricuspid regurgitation 3D TASA (cm2) r p Value 2D diameter (4CH) 2D diameter (PLAX) r p Value r p Value 3D EROA (mm2) 0.78 <0.0001 0.408 <0.001 0.114 NS 3D PISA surface (cm2) 0.727 <0.0001 0.418 <0.001 0.105 NS 3D Regurgitant volume (ml) 0.754 <0.0001 0.453 0.001 0.184 NS Miglioranza G. et al. EuroEcho 2014 (P#1004)

Tricuspid Annulus in Functional Regurgitation 24 pts with severe (30%) and non severe (70%) functional tricuspid regurgitation 3D TA geometry parameters 3D EROA (mm2) 3D PISA (cm2) r r p Value p Value 3D Regurgitant volume (ml) r p Value Perimeter (cm) 0.697 0.001 0.680 <0.001 0.754 0.001 Surface area (cm2) 0.719 0.001 0.679 <0.001 0.750 <0.001 Long axis (cm) 0.734 0.001 0.649 0.001 0.715 0.002 Short axis (cm) 0.685 0.002 0.665 <0.001 0.707 0.002 Cavalli G et al. EuroEcho 2014 (P#1281)

Tricuspid Annulus in Functional Regurgitation 43 pts with severe (30%) and non severe (70%) functional tricuspid regurgitation TA geometry parameters RV volume (ml) RA volume (ml) r r p Value p Value Perimeter (cm) 0.698 <0.001 0.768 <0.001 Surface area (cm2) 0.650 <0.001 0.760 <0.001 Long axis (cm) 0.550 <0.001 0.815 <0.001 Short axis (cm) 0.599 <0.001 0.699 <0.001 Muraru D et al. EuroEcho 2014 (P#552)

Tricuspid Annulus in Functional Regurgitation TR is highly dependent on annulus dilation 40% increase in TA is enough for the valve to leak (FMR: 75%) Spinner E et al. Circulation 2011

Right Ventricular Papillary Muscles Courtesy of Dr William Edwards, Mayo Clinic, Rochester, MN In comparison with MV, PMs are smaller, widely separated and carrying chordae to a single leaflet, allowing a greater leaflet separation if annulus and RV cavity dilate Badano LP, Muraru D, Enriquez-Sarano M. Eur Heart J 2013

Valve Leaflet Tenting TV tenting volume by 3DE (accounting for both enlarged annulus area and leaflet tenting) is the major determinant of residual functional TR after annuloplasty Tenting volume >2.3 cm 3 The major goal of TV repair is an effective reduction of TV tenting volume; however, current annuloplasty techniques worsen leaflet tethering and actually increase TV tenting volume Min SY et al. Eur Heart J 2010

Valve Tenting in Functional Regurgitation Not all patients with annulus dilation have significant TR Annulus area = 11.0 cm2 Tenting vol = 1.2 cm3 Mild TR Annulus area = 11.2 cm2 Tenting vol = 3.3 cm3 Severe TR For the same annulus size, variation in leaflet tenting and size may account for TR occurence In case of very enlarged RVs, downsizing ring annuloplasty should be associated with leaflet augmentation and/or PMs repositioning techniques Spinner E et al. Circulation 2011

Predictors of Residual Regurgitation After Tricuspid Annuloplasty TV tenting volume (annulus size and leaflet tenting) measured before and after annuloplasty is a major determinant of residual functional TR regardless of the TR quantification method employed (VC or jet area) Min SY et al. Eur Heart 2010

Clinical Case 63-yr-old caucasian man Functional TR treated by downsizing ring annuloplasty

Tricuspid Annuloplasty and Wrong Annulus Sizing Case #6 Case #7

Conclusions TV annulus and leaflets are different than MV annulus and leaflets, and the same quantification algorithms/tools not necessarily work the same for both valves Conventional 2D/Doppler echocardiographic parameters do not seem to povide accurate quantification of tricuspid regurgitation severity TV annulus 3D shape and function are key players in the development of functional TR, and 2D echo is clearly inadequate to quantify them A dedicated semi-automated software for tricuspid valve analysis by 3D echo commercially-available is highly needed Future studies will confirm if a more accurate quantification of tricuspid annulus size and regurgitation severity will translate in better selection of patients for tricuspid valve repair/annuloplasty